1. Home
  2. MERLOT Materials
  3. Material Detail: Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine - PubMed

Material Detail

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine - PubMed

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine - PubMed

A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).

Keyword:
COVID-19
Disciplines:
Go to Material 
Bookmark / Add to Course ePortfolio
Create a Learning Exercise
Add Accessibility Information
Rate
Add a Comment

Quality

  • User Rating
  • Comments
  • Learning Exercises
  • Bookmark Collections
  • Course ePortfolios
  • Accessibility Info

More about this material

Material Type:
Reference Material
Date Added to MERLOT:
August 17, 2021
Date Modified in MERLOT:
August 17, 2021
Author:
Unknown (Know the author?)
Submitter:
Mary Bemker
Primary Audience:
College Upper Division, Graduate School, Professional
Technical Format:
Website
Mobile Compatibility:
Not specified at this time
Technical Requirements:
Accessed via Google Chrome.
Language:
English
Cost Involved:
No
Source Code Available:
Yes
Creative Commons:
Unknown

Browse...

Disciplines with similar materials as Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine - PubMed
People who viewed this also viewed
Other materials like Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine - PubMed

Comments

Log in to participate in the discussions or sign up if you are not already a MERLOT member.